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Materials of a Mini-syMposiuM 
“new trends in cancer research 
and innovative tuMor vaccines” 
held on May 11, 2017 during the vactrain suMMer school 
in Kyiv, uKraine
A mini-symposium “New Trends in Cancer Re-
search and Innovative Tumor Vaccines” was held 
on May, 11 of 2017 during the VACTRAIN summer 
school at R.E. Kavetsky Institute of Experimental Pa-
thology, Oncology and Radiobiology (IEPOR) of the 
NAMS of Ukraine, Kyiv, Ukraine.
On this day, young researchers have presented re-
sults of their current work, along with few keynote lec-
tures. The main focus of this event was to understand 
the modern trends to find the new markers to diagnose 
cancer disease and new targets for cancer vaccines. 
Also, there was a discussion on novel cancer vaccines.
The deputy director of IEPOR Associated profes-
sor Lubov Buchynska welcomed the participants 
and wished the fruitful discussion, concerning new 
approaches in the development of cancer vaccines. 
Professor Chanchal Mitra (Hyderabad University, 
India) gave a wide overview on miRNAs that play 
an important role in cancer development. Associ-
ated professor Elena Kashuba (IEPOR) presented 
the new data on a role of mitochondrial ribosomal 
protein S18-2 as the new oncoprotein and a putative 
target for cancer vaccine. More data and the future 
perspectives are described in abstracts of young 
researchers from Ukraine, Belarus, Latvia, and Lithu-
ania (see below).
Concluding mini-symposium, supported by the 
VACTRAIN of Horizon 2020 program, Elena Kashuba 
thank VACTRAIN for the possibility of schooling the 
young researchers with an aim to help them to became 
the critically thinking open-minded researchers. The 
importance of scientific collaboration was also enligh-
tened. Definitely, this summer school resulted in the 
enhanced knowledge in medical science and helped 
to plan the new fruitful scientific works with the aim 
to combat cancer.
selected abstracts
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One of the directions of gene therapy is curative 
cancer treatment. During transformation, normal 
cells start to propagate uncontrollably and lose 
the ability to undergo apoptosis, resulting in tu-
mor formation. Expression of apoptosis inhibitors 
(BCL-2 family proteins) can be downregulated 
at a post-translational level by means of RNA inter-
ference (RNAi), i.e. by a process of highly selective 
gene silencing. RNAi effectors — siRNA (small 
interfering RNA) or microRNA are able to cleave 
mRNA, using the cellular machinery (Burlacu, 
2003). The major limit of such gene therapy appli-
cation is an absence of effective delivery of nucleic 
acids (siRNA) into the target cells (Songet et al., 
2005).
Dendrimers are synthetic polymers, highlighted 
for gene delivery, due to their monodispersity, pre-
determined tree-like structure, stability, low visco sity 
of their solutions and a large number of charged 
end groups. Cationic dendrimers can complex with 
nucleic acids by self-assembly, making complexes 
called “dendriplexes” (Wang et al., 2010).
Different kinds of dendrimers were tested 
as delivery systems for different RNAi effectors. 
It was revealed that PAMAM (carbosilane and 
phosphorous-containing dendrimers) form stable 
complexes with small acting RNAs by self-assem-
bling in up to 1 µm in size. In contrast to others, 
phosphorous dendrimers are insensitive to heparin 
impact, thus indicating not only electrostatic in-
teraction within the dendriplex (Ionov et al., 2015). 
Cytotoxicity studies on HeLa (cervical cancer) and 
HL-60 (promyelocytic T-leukemia) cell lines showed 
the synergism in action of siRNAs specific for various 
anti-apoptotic proteins, in comparison with treatment 
with each single siRNA. This was observed when 
siRNAs were delivered by cationic dendrimers. In our 
experiments, the cytotoxicity of siRNA/dendrimer 
complexes showed a dual nature, based on three 
mechanisms: apoptosis, autophagy, and necrosis. 
The siRNA induced apoptosis and, moreover, den-
drimers themselves may induce all above, depend-
ing on the chemical nature of dendrimer (Dzmitruk 
et al., 2015).
This work was supported by 2 grants from the 
Belarusian Republican Foundation for Fundamen-
tal Research No. B15RM-060 and No. B15CO-041, 
a Marie Curie International Research Staff Exchange 
Scheme Fellowship within the 7th European Com-
munity Framework Programme, project No. PIRSES-
GA-2012-316730 NANOGENE.
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siMultaneous cd150 and cd180 ligation  
Mutually inhibit aKt and MapK signal 
transduction pathways in the chronic 
lyMphocytic leuKeMia b cells
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Combination of input signals from cell surface recep-
tors (e.g. BCR, CD140, BAFFR, TLR) in B-cell malignancies 
underlies disease outcome. It was shown that cell surface 
CD150 (csCD150) and CD180 (csCD180) expression 
in chronic lymphocytic leukemia (CLL) correlates with 
favourable prognosis.
We found that csCD150 expression has strong posi-
tive correlation with csCD180 expression in CLL cases (r = 
0.75, p = 0.0001). Moreover, CD150 showed the highest 
level of colocalization with CD180 (R = 0.88 ± 0.13; R[r] = 
0.87 ± 0.1) at a cell membrane of CLL B cells. To determine 
the biological significance of simultaneous CD150 and 
CD180 expression in CLL pathobiology we performed in vi-
tro stimulation assay followed by signaling pathways analy-
sis. CD150 or CD180 crosslinking on CLL B cells alone 
resulted in activation of Akt, mTORC1, ERK1/2, p38MAPK 
and JNK1/2 pathways. Both CD150 and CD180 receptors 
affect protein synthesis through p70S6K phosphorylation 
and transmit pro-survival signals via Akt-mediated GSK3β 
and FOXO1/FOXO3a transcription factors inhibition. It was 
surprising that simultaneous CD150 and CD180 liga-
tion blocked Akt, mTORC1 as well as MAPK pathways 
activation in CLL B cells. Moreover, in the absence 
of CD150 and CD180 on cell surface, both antigens were 
expressed on the protein level in the cytoplasm. Intracellu-
lar distribution of CD150 and CD180 in CLL B cells showed 
different pattern. CD150 antigen was colocalized with 
markers of endoplasmic reticulum, Golgi apparatus, early 
endosomes, but only trace amount was detected in lyso-
somes. In contrast, CD180 was detected preferentially 
in early endosomes (R = 0.60 ± 0.10; R[r] = 0.59 ± 0.10). 
It could be concluded that malignant CLL B cells try to es-
cape simultaneous cell surface CD150 and CD180 expres-
sion since combined ligation of these receptors leads 
to blocking of pro-survival pathways.
adaptor protein ruK/cin85 increases 
tuMorigenicity of MaMMary 
adenocarcinoMa cells via proMoting 
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Adaptor proteins serve as molecular platforms for 
multimolecular complexes assembly and thereby regulate 
intracellular signaling. Our previous results demonstrated 
that tumors (including breast cancer) are character-
ized by increased expression of adaptor protein Ruk/
CIN85 in comparison to normal tissues. This adaptor plays 
a critical role in several cellular processes, such as ligand-
induced endocytosis of RTKs, intracellular vesicular 
trafficking, adhesion, motility, and survival. In this study 
we investigated the effect of Ruk/CIN85 on tumorigenicity 
of mammary adenocarcinoma cells.
As a model we used mouse 4T1 mammary adeno-
carcinoma cells with stable overexpression (RukUp) and 
downregulation (RukDown) of Ruk/CIN85. Motility and 
invasiveness of these cells were analyzed by scratch 
test and Boyden chamber assay. The effectiveness 
of metastasіs formation was studied using experimental 
metastasis assay. qPCR and Western blotting were carried 
out to evaluate gene and protein expression.
We demonstrated that Ruk/CIN85 overexpression 
leads to elevation of motility and invasiveness in vitro and in-
creased the ability to produce lung metastasis in vivo. Also, 
we demonstrated increased expression of mesenchymal 
markers in RukUp cells and epithelial markers in RukDown 
cells that mean Ruk/CIN85 promotes EMT in 4T1 cells.
identification of novel Molecular 
and genetic MarKers for early 
detection of epithelial tuMors 
and prognosis of the course of disease
Oksana Mankovska, Vladimir Kashuba
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NAS of Ukraine, Kyiv, Ukraine
E-mail: mankovsska@gmail.com
The main topic of our research is the identification 
of molecular and genetic markers for the early detection 
of epithelial tumors and prognosis of the disease. Early de-
tection of cancer can lead to more successful treatment, 
thus, significantly increasing the chances for recovery. The 
investigation of non-invasive diagnostic tools, which can 
be used in clinical practice, is now the main focus of on-
cology. This problem can be solved by using of molecular 
nucleic acid markers that are present in biological fluids 
(serum, urine, semen etc).
We have developed several useful and effective ap-
proaches for the investigation of molecular and genetic 
markers. We are studying both, genetic and epigenetic 
changes in cancers of different types, using a broad-
scale screening of their presence in clinical samples. The 
techniques and methods we use allow us to obtain reliable 
results and propose them for implementation in clinical 
practice.
diagnostic value of neutrophil/
lyMphocyte ratio in hepatocellular 
carcinoMa and focal nodular 
huperplasia: a pilot study
Dzeina Mezale1, Ilze Strumfa1, Andrejs Vanags2, 
Ilze Fridrihsone1, Polina Viktorova1
1Department of Pathology, Riga Stradins University, 
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Hepatocellular carcinoma (HCC) is the sixth most 
common malignancy and the third most common 
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cause of cancer death worldwide (Jain et al., 2017). 
Distinguishing a well-differentiated HCC from benign 
liver nodules, such as focal nodular hyperplasia 
(FNH), may be difficult in some cases, particularly 
in small needle core biopsies (Coston et al., 2008), 
thus additional diagnostic markers are essential. 
Routinely available marker of the systemic inflam-
matory response such as neutrophil — lymphocyte 
ratio (NLR) has recently been reported as a predictor 
of HCC; an ele vated level indicating a poor prognosis 
(Xiao et al., 2014). The aim of the present study was 
to examine whether NLR could be used as an ad-
ditional diagnostic marker distinguishing between 
HCC and FNH.
In a retrospective pilot study, 14 patients with 
morphologically confirmed HCC and 6 patients with 
FNH were included. NLR was defined as the absolute 
neutrophil count divided by the absolute lymphocyte 
count. Complete blood count levels were used to cal-
culate NLR. Data were evaluated using IBM SPSSv23. 
To assess data distribution, an independent-samples 
Kolmogorov — Smirnov test was performed. Descrip-
tive statistic evaluation was performed, including 
detection of median values and interquartile range 
IQR = Q3–Q1. To compare groups, independent 
samples median test and Fisher exact significance 
test were used. The significance level was set at 0.05.
The median value of NLR in FNH group was 
1.67 (N = 6; Q1 = 1.20; Q3 = 2.57; IQR = 1.37). The 
median NLR of the patients with HCC was 2.49 (N = 14; 
Q1 = 1.97; Q3 = 4.55; IQR = 2.58), which is higher 
comparing with FNH group, but the difference was 
statistically insignificant (p = 0.141).
Concluding, we showed that i) A complete 
blood count with following calculation of NLR 
is widely available blood test, which has a potential 
to be a useful additional marker distinguishing be-
tween HCC and benign liver nodules, such as FNH; 
ii) The median NLR in HCC patient group was higher 
than in FNH group (1.67 and 2.49, respectively), 
which corresponds to the available scientific data, 
but the difference was found to be statistically insig-
nificant. However, further research in a larger group 
is clearly required.
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We have found that S18–2 is involved in regula-
tion of the RB-dependent pathway. It binds to both 
hypo- and hyperphosphorylated RB. The binding be-
tween RB and S18–2 is promoted when cytoplasmic 
S18–2 is targeted to the nucleus, and this disrupts 
the association of E2F1 with RB, as indicated by the 
increased level of free E2F1 in the nucleus (Kashuba 
et al., 2008). This presumably lifts the RB-dependent 
block of S phase entry. We have also found that 
overexpression of the human S18–2 immortalized 
primary rat embryonic fibroblasts that showed 
properties of embryonic stem cells (Kashuba et al., 
2009). Elevated expression of S18–2 in stem cells 
(our findings and analysis of published microarray 
data) raises the question of whether this protein co-
operates with the RB protein in cell differentiation 
and oncogenesis.
We aimed to seek a connection between the ex-
pression of RB and S18–2 in Rb1–/– mouse embry-
onic fibroblasts and stemness. We hypothesized that 
simultaneous expression of both proteins at the high 
levels might support stemness. Transfections, inocu-
lation into SCID mice, directed differentiation, qPCR, 
immunostaining, immunohistochemistry, Western 
blotting, zebrafish embryogenesis were used in the 
present work.
We showed that S18–2 protein, together with 
RB, plays a crucial role in cell de-differentiation. 
We have also found that overexpression of S18–2 and 
RB is needed for maintenance of cell stemness. Such 
cells can differentiate into various cell lineages under 
certain conditions. The presence of RB and simultane-
ous expression of S18-2 at high levels are required for 
the cell stemness.
inhibition of ire1 signaling affects 
the eXpression of genes encoding 
glucocorticoid receptor and soMe 
related proteins in u87 glioMa cells
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Glucocorticoid receptor (nuclear receptor subfam-
ily 3, group C, member 1; NR3C1) plays an important 
role in the regulation of numerous metabolic and 
proliferative processes, including tumorigenesis and 
metabolic diseases. Regulation of these processes 
by glucocorticoids is preferentially stress-dependent, 
but the involvement of the endoplasmic reticulum (ER) 
stress signaling has not been explored yet.
The aim of the present investigation was to ex-
amine the effect of inhibition of ER stress signaling 
mediated by IRE1 (inositol requiring enzyme 1), which 
is a central mediator of the unfolded protein response, 
on the expression of genes encoded NR3C1 and 
some related proteins (SGK1, SGK3, NCOA1, NCOA2, 
ARHGAP35, NRIP1, and NNT) and their hypoxic regu-
lation in U87 glioma cells for evaluation of their possible 
significance in the control of glioma growth.
The expression of NR3C1, SGK1, SGK3, NCOA1, 
NCOA2, ARHGAP35, NRIP1, and NNT genes in U87 glio-
ma cells transfected by empty vector pcDNA3.1 (control) 
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and cells without IRE1 signaling enzyme function (trans-
fected by dnIRE1) upon hypoxia was studied by qPCR.
We have shown that inhibition of IRE1 signaling en-
zyme function up-regulates the expression of NR3C1, 
SGK1, NCOA1, NCOA2, ARHGAP35, and NNT genes 
in U87 glioma cells in comparison with the control glioma 
cells, being more significant changes for NR3C1, SGK1, 
and NNT genes. At the same time, the expression 
of SGK3 and NRIP1 genes is strongly down-regulated 
in glioma cells upon inhibition of IRE1. We have also 
shown that hypoxia increases the expression of NR3C1, 
SGK1, NCOA2, ARHGAP35, and NNT genes but de-
creases SGK3, NRIP1, and NCOA1 genes expression 
in control glioma cells. Moreover, the inhibition of both 
enzymatic activities (kinase and endoribonuclease) 
of IRE1 in U87 glioma cells enhances the effect of hy-
poxia on the expression of SGK1, SGK3, and NNT genes 
but decreases the sensitivity of NR3C1 gene to hypoxic 
condition. Furthermore, the expression of NCOA1 gene 
is resistant to hypoxia in control glioma cells, but 
NCOA2, NRIP1, and ARHGAP35 genes are resistant 
to this condition in glioma cells without functional activity 
of IRE1 signaling enzyme.
Results of this investigation demonstrate that in-
hibition of IRE1 signaling enzyme function affects the 
expression of NR3C1, SGK1, SGK3, NCOA1, NCOA2, 
ARHGAP35, NRIP1, and NNT genes in U87 glioma 
cells in the gene specific manner and that all these 
genes are regulated by hypoxia preferentially through 
IRE1 signaling pathway of ER stress.
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Despite numerous studies that aimed to define the 
molecular mechanisms that underlay formation and 
progression of prostate tumors, markers of advanced 
prostate cancer are still not elaborated. The objective 
of our investigation was an analysis of relative gene 
expression of a set of cancer-associated genes, previ-
ously selected based on a work with the prostate cancer 
cell lines. We studied the following cancer-associated 
genes in the clinical samples of prostate tumors — 
TGFB1, IL1B, FOS, EFNA5, TAGLN, PLAU, and EPDR1.
To study the expression of the abovementioned 
genes, a total RNA from 16 prostate adenomas, 37 ad-
enocarcinomas and 29 conventionally normal tissues 
were isolated. qPCR was performed to analyze the 
gene expression pattern. Immunohistochemistry was 
conducted to determine the expression of the TGFβ1, 
FOS, TAGLN, and PLAU proteins.
Alterations in the relative gene expression levels 
were found for TGFB1, IL1B, FOS, EFNA5, TAGLN, 
PLAU, and EPDR1 genes in all analyzed groups. For 
TGFB1, FOS, TAGLN, and PLAU genes obtained results 
were confirmed on the protein level. FOS protein was 
increased during progression from adenoma to ag-
gressive prostate cancer. Meanwhile, levels of TGFβ1, 
TAGLN, and PLAU proteins were decreased in ad-
vanced prostate cancer.
Concluding, the obtained results might indicate 
that TGFB1, FOS, TAGLN, and PLAU are potential bio-
markers for prostate cancer. Moreover, FOS gene may 
be a putative target for anti-cancer therapy. However, 
these results are preliminary and it requires the further 
investigations.
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The incidence of type 2 diabetes mellitus (T2D) has 
become an epidemic, increasing the risk of cardiovas-
cular diseases and premature death. The global T2D 
prevalence is 8.3% with the highest burden in develop-
ing countries. Metformin is a first-line therapy in T2D 
treatment, but pharmacodynamics of metformin is still 
not clear. There is a variable efficiency observed for 
metformin therapy; furthermore, nearly one-third 
of T2D patients do not respond to it.
So far, there are no validated biomarkers that would 
predict the effectiveness of diabetes medications 
and the patient’s responses to treatment. Epigenetic 
signatures are considered to be promising biomarkers 
for the evaluation of the therapeutic efficiency in meta-
bolic diseases. The impact of metformin on epigenetic 
regulation has not been described.
Studies on metformin’s mechanism of action and 
development of new epigenetic biomarkers will allow 
to predict the effectiveness and the potential toxicity 
of metformin in T2D patients.
The aim of the study is to determine the epigenetic 
patterns related with T2D and response to antidiabetic 
drug therapy. The main objectives are the following: 
i) To identify metformin-induced novel DNA meth-
ylation and RNA expression signatures in healthy 
individuals and T2D patients; ii) To validate potential 
epigenetic biomarkers in a large cohort of T2D patients 
after long-term metformin therapy; iii) To estimate the 
concordance between epigenetic patterns derived 
from white blood cells with those from target tissues, 
by analysis of DNA methylation and RNA expression 
in mice; and iv) To develop an epigenetic-based 
algorithm for prediction of efficacy and side-effects 
of metformin therapy.
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